Examkin

Soru

Zorluk: Çok zorPharmacologic Interventions

A 67-year-old woman with end-stage renal disease on hemodialysis is admitted for a severe diabetic foot infection. She is treated with intravenous vancomycin and prophylactic subcutaneous unfractionated heparin. On hospital day 7, she develops sudden-onset dyspnea and pleuritic chest pain. Vital signs show a heart rate of 112/min, blood pressure of 130/80 mmHg, and oxygen saturation of 89% on room air. Computed tomography pulmonary angiography confirms a new segmental pulmonary embolism. Laboratory studies reveal a platelet count of 65,000/mm³, which has fallen from a baseline of 240,000/mm³ on admission. The 4Ts score is calculated as 7, indicating a high probability of heparin-induced thrombocytopenia (HIT). The clinical team decides to manage her acute thrombosis and bridge her to long-term oral anticoagulation with a vitamin K antagonist.

Arrange the following pharmacologic orders in the strict chronological sequence required to safely manage this patient's coagulopathy from the acute phase through the transition to outpatient therapy.

  1. 1Discontinue subcutaneous unfractionated heparin
  2. 2Initiate continuous intravenous argatroban infusion
  3. 3Initiate oral warfarin therapy
  4. 4Discontinue intravenous argatroban infusion

Cevap

The correct chronological sequence is: 1) Discontinue subcutaneous unfractionated heparin, 2) Initiate continuous intravenous argatroban infusion, 3) Initiate oral warfarin therapy (upon platelet recovery), and 4) Discontinue intravenous argatroban infusion (after therapeutic overlap).
The safe management of Heparin-Induced Thrombocytopenia (HIT) requires a rigid chronological protocol to prevent catastrophic thrombotic complications. The offending agent (heparin) must be stopped immediately. Because the patient has an active pulmonary embolism and a highly prothrombotic state, an alternative non-heparin anticoagulant must be started concurrently. Given her end-stage renal disease, argatroban is the anticoagulant of choice due to its hepatic clearance. Transitioning to outpatient warfarin therapy requires strict timing: it must NEVER be started while the patient is actively thrombocytopenic due to the risk of venous limb gangrene from precipitous Protein C depletion. Therefore, warfarin is only initiated once the platelet count recovers to >150,000/mm³. Finally, because warfarin takes days to achieve full antithrombotic efficacy, the argatroban infusion must overlap with warfarin for a minimum of 5 days and until the INR is therapeutic for two consecutive days before it can be discontinued.

Adım Adım Çözüm

1
Discontinue subcutaneous unfractionated heparin
Halts the administration of the inciting antigen.
Continuing any form of heparin fuels the formation of IgG antibodies against the heparin-platelet factor 4 (PF4) complex, driving further platelet activation and thrombosis.
2
Initiate continuous intravenous argatroban infusion
Provides immediate, safe therapeutic anticoagulation.
Patients with HIT and thrombosis require immediate non-heparin anticoagulation. Argatroban (a direct thrombin inhibitor) is chosen here because its hepatic clearance makes it safe for a patient with end-stage renal disease, unlike bivalirudin or fondaparinux.
3
Initiate oral warfarin therapy
Begins the transition to long-term oral anticoagulation.
Warfarin initiation is strictly contraindicated during the acute thrombocytopenic phase of HIT. It must be delayed until platelets recover to at least 150,000/mm³ to prevent venous limb gangrene caused by rapid protein C depletion.
4
Discontinue intravenous argatroban infusion
Completes the transition to monotherapy with a vitamin K antagonist.
Argatroban can only be discontinued after an adequate overlap with warfarin (minimum of 5 days) AND once the INR has been therapeutic (typically 2.0-3.0) for at least 48 hours, ensuring full suppression of vitamin K-dependent clotting factors.

Anahtar Kavram

Pharmacologic bridging sequence for Heparin-Induced Thrombocytopenia (HIT) transitioning to Warfarin
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru